T1DM in children

Definition & Classification

• Chronic metabolic syndrome.
• Absolute insulin deficiency.
• Result of pancreatic beta-cell destruction.
• Lifelong exogenous insulin replacement mandated.

Category	Etiology	Key Features
Type 1A	Immune-mediated	Presence of autoantibodies.
Type 1B	Idiopathic	Non-autoimmune, negative immune markers, severe insulinopenia.

Epidemiology

• Accounts for 10% global diabetes cases.
• Predominant form in childhood/adolescence.
• High geographic/ethnic variation.
• Peak incidence Scandinavia (Finland: 35/100,000 annually).
• Lower incidence Asian/African descent.

Bimodal Age Distribution

Peak	Age Range	Putative Mechanism
First Peak	5-7 years	Increased viral exposure upon school entry.
Second Peak	Puberty	Physiological insulin resistance (growth hormone/sex steroid surges).

Etiology & Pathogenesis

Genetic Susceptibility

• Highly polygenic disorder.
• 40-50% heritable risk derived from Human Leukocyte Antigen (HLA) region.

Locus / Gene	Chromosome / Location	Key Characteristics
IDDM1	MHC chromosome 6p21	Contains class II HLA alleles DR3, DR4, haplotypes DQB1_0302, DQB1_0201.
HLA-DQ Beta Chain	-	Absence of aspartic acid at position 57 alters antigen presentation.
IDDM2	Chromosome 11 (INS gene)	VNTR polymorphism regulates thymic insulin expression/central tolerance.
Non-HLA Genes	Various	PTPN22, CTLA4, IL2RA, IFIH1, ERBB3, AIRE (immune regulation/T-cell activation).

Environmental Triggers

• Monozygotic twin concordance 30-65% (obligatory environmental role).
• Viral mechanisms: Direct beta-cell toxicity, molecular mimicry, superantigen-mediated activation.
  • Implicated viruses: Enteroviruses (Coxsackievirus B1/B4), congenital rubella, cytomegalovirus.
• Dietary factors studied: Early introduction cow’s milk/gluten.
• Microbiome: Decreased diversity, deficient butyrate-producing organisms.
• Vitamin D deficiency implicated.

Autoimmunity & Natural History

• Initial asymptomatic insulitis (T-lymphocyte/macrophage infiltration).
• Predictive biomarkers: ICA, GAD65, IA-2A (ICA512), IAA, ZnT8A.
• Multiple autoantibodies convey high positive predictive value for clinical disease.

Stage	Biomarkers	Glycemic Status	Symptoms
Stage 1	$\ge$ 2 autoantibodies	Normoglycemia	Asymptomatic.
Stage 2	$\ge$ 2 autoantibodies	Dysglycemia (Impaired fasting/tolerance)	Asymptomatic.
Stage 3	$\ge$ 2 autoantibodies	Hyperglycemia	Clinical onset.

Pathophysiology

• Insulin: Primary anabolic hormone (promotes carbohydrate/lipid/protein synthesis, restrains degradation).
• Beta-cell destruction induces low-insulin catabolic state (mimics exaggerated starvation).
• Absolute deficiency impairs peripheral glucose uptake (muscle/adipose).
• Releases of hepatic glycogenolysis/gluconeogenesis suppression.
• Uninhibited hepatic overproduction + impaired peripheral utilization induces marked systemic hyperglycemia.
• Plasma glucose exceeds renal threshold (180 mg/dL or 10 mmol/L).
• Glycosuria causes obligate osmotic diuresis.
• Water/electrolyte loss precipitates physiological stress.
• Counterregulatory hypersecretion (epinephrine, cortisol, GH, glucagon) exacerbates insulin resistance.

Primary Mechanisms of Dysglycemia

Category	Pathophysiological Mechanism	Clinical Phenotypes
1. Autoimmune Beta-Cell Destruction	T-lymphocyte and macrophage infiltration of pancreatic islets (insulitis). Progressive autoimmune destruction leads to absolute insulin deficiency and lifelong exogenous insulin dependence.	Type 1A Diabetes Mellitus.
2. Insulin Resistance with Beta-Cell Failure	Central adiposity drives ectopic lipid deposition (liver, skeletal muscle), inducing peripheral insulin resistance. Beta cells initially compensate via hyperinsulinemia, ultimately failing due to chronic glucotoxicity and lipotoxicity.	Type 2 Diabetes Mellitus.
3. Genetic Defects of Beta-Cell Function	Monogenic mutations disrupting pancreatic beta-cell insulin secretion. Mechanisms include altered glucose sensing (glucokinase mutations), KATP channel activation keeping channels open (KCNJ11, ABCC8), or defective transcription factors,.	Maturity-Onset Diabetes of the Young (MODY), Neonatal Diabetes,,.
4. Genetic Defects in Insulin Action	Profound post-receptor signaling failure. Caused by severe insulin receptor gene mutations (INSR) or absence of adipose tissue restricting normal insulin binding and action,,.	Donohue Syndrome (Leprechaunism), Rabson-Mendenhall Syndrome, Lipoatrophic Diabetes,,.
5. Exocrine Pancreatic Disease	Structural destruction of pancreatic tissue. Progressive islet amyloid deposition, inflammation, or physical loss of beta-cell mass restricting insulin secretion capacity,,.	Cystic Fibrosis-Related Diabetes (CFRD), Post-pancreatectomy diabetes,.
6. Drug or Chemical-Induced Diabetes	Pharmacological agents inducing direct beta-cell toxicity, diminishing insulin release, or triggering severe peripheral insulin resistance.	Immunosuppressants (Cyclosporine, Tacrolimus, Sirolimus), L-Asparaginase, Glucocorticoid therapy.

Clinical Manifestations

• Abrupt onset over several weeks.
• Occurs after 80-90% functional beta-cell mass destruction.

Manifestation	Underlying Pathophysiology / Clinical Pearl
Polyuria	Driven by obligate osmotic diuresis.
Polydipsia	Compensatory response to volume depletion.
Polyphagia	Paradoxically accompanies significant unexplained weight loss (catabolic state).
Enuresis	Nocturnal enuresis in previously toilet-trained child (high-yield indicator).
Constitutional	Profound fatigue, lethargy, weakness, malaise.
Fungal Infections	Vulvovaginal candidiasis (females), candidal balanitis (males) due to chronic glycosuria.
DKA	Rapid evolution to life-threatening Diabetic Ketoacidosis via unchecked lipolysis/ketogenesis if unrecognized.

Diagnostic Criteria

• Relies on standardized ADA/WHO criteria.

Test	Diagnostic Threshold	Conditions
Fasting Plasma Glucose (FPG)	$\ge$ 126 mg/dL (7.0 mmol/L)	Overnight fast $\ge$ 8 hours.
Oral Glucose Tolerance (OGTT)	$\ge$ 200 mg/dL (11.1 mmol/L)	2-hour mark, 1.75 g/kg load (max 75g).
Random Plasma Glucose	$\ge$ 200 mg/dL (11.1 mmol/L)	Presence of classic hyperglycemia symptoms.
Hemoglobin A1c (HbA1c)	$\ge$ 6.5% (48 mmol/mol)	Utility debated in pediatrics due to age-related variations.

Differential Diagnosis: T1DM vs. T2DM

Marker	Type 1 Diabetes (T1DM)	Type 2 Diabetes (T2DM)
C-peptide	Low or undetectable.	Normal or significantly elevated (compensatory hyperinsulinemia).
Autoantibodies	Positive (GAD, ICA, IAA, IA-2A, ZnT8A).	Typically Negative.
Overlap Syndrome	-	”Double Diabetes”: 10-30% obese T2DM youth test positive for autoantibodies.

Management

Goals of Therapy

• Achieve glucose/HbA1c near normal physiological range.
• Prevent/delay microvascular and macrovascular complications.
• Balance objective against severe hypoglycemia risk.
• Standard pediatric target: HbA1c < 7.0% (<53 mmol/mol).
• Individualize targets based on hypoglycemia history/unawareness/technology access.

Insulin Therapy

Dosing

• Lifelong exogenous insulin mandatory.
• Prepubertal Requirement: 0.6 to 0.8 units/kg/day.
• Pubertal Requirement: 1.0 to 1.2 units/kg/day (overcomes GH-induced transient resistance).

Preparations

Class	Examples	Onset	Peak	Duration	Clinical Role
Rapid-Acting	Lispro, Aspart, Glulisine	5-10 min	1-3 hr	3-4 hr	Pump infusions (CSII), premeal bolusing (no hexamer formation).
Short-Acting	Regular	30-60 min	2-4 hr	5-8 hr	Standard of care for continuous IV infusion during DKA management.
Intermediate	NPH	1-2 hr	2-8 hr	16-24 hr	Introduces high variability/hypoglycemia risk due to distinct peak.
Long-Acting	Glargine, Detemir, Degludec	1-2 hr	Peakless	$\ge$ 20-24 hr	Ideal basal insulin, suppresses hepatic gluconeogenesis overnight/daily.

Delivery Regimens

• Objective: Mimic continuous basal secretion + intermittent mealtime bursts.

Regimen	Mechanism	Description
MDI	Multiple Daily Injections	Basal-bolus concept: Long-acting analog 1-2x daily + rapid-acting bolus 10-15 min pre-meal.
CSII	Continuous Subcutaneous Infusion	External pump infuses rapid-acting analog at customized basal rates + user-triggered meal boluses.
Artificial Pancreas	Automated Insulin Delivery	Closed-loop system links CGM to pump via control algorithm; automatically modulates basal rates/suspends for hypoglycemia.

Glucose Monitoring

Modality	Acronym	Method & Features
Self-Monitoring	SMBG	Capillary fingerstick glucometer; minimum 4-6 checks/day (pre-meal, bedtime, midnight).
Continuous	CGM	Subcutaneous sensor measures interstitial glucose every 5 mins; provides real-time trends/alarms, eliminates routine fingersticks.

Medical Nutrition Therapy

• No highly restrictive “diabetic diet”.
• Goal: Normal, healthy diet providing 100% RDA energy for growth/puberty.
• Foundation: Carbohydrate counting.

Dosing Calculations

• Insulin-to-Carbohydrate Ratio (ICR): Grams of carbohydrate covered by 1 unit insulin.
  • Estimated by “Rule of 500” (500 / Total Daily Dose).
• Insulin Sensitivity Factor (ISF): mg/dL blood glucose drop per 1 unit rapid-acting insulin.
  • Estimated by “Rule of 1800” (1800 / Total Daily Dose).

Macronutrient Distribution

Nutrient	Target % Calories	Specific Restrictions
Carbohydrates	50-55%	-
Protein	15-20%	-
Fats	25-35%	Limit saturated fats <10%, cholesterol <300 mg/day (mitigate cardiovascular risk).

The Honeymoon Phase (Partial Remission)

• Rapid reversal of profound insulin resistance/glucotoxicity upon starting insulin.
• Transient partial recovery of residual beta-cell secretion.
• Exogenous insulin requirements drastically drop (< 0.5 units/kg/day).
• Duration variable (weeks to months, rarely > 1 year).
• Clinical imperative: Never completely discontinue exogenous insulin (maintains beta-cell function, prevents abrupt decompensation).

Acute Complications

Hypoglycemia

• Greatest acute barrier to optimal targets.
• Defined as blood glucose < 70 mg/dL.

Category	Symptoms	Underlying Mechanism
Autonomic	Sweating, palpitations, severe tremor, intense hunger.	Epinephrine release.
Neuroglycopenic	Severe headache, profound confusion, lethargy, drowsiness, intractable seizures.	Central nervous system glucose deprivation.
Unawareness	Severe neuroglycopenia lacking autonomic warning signs.	Blunted epinephrine response due to frequent hypoglycemia.

Management of Hypoglycemia

• Mild/Moderate: Oral 15g rapid simple carbohydrate (glucose tablets/juice), followed by complex carbohydrate snack.
• Severe (Altered sensorium/convulsions/inability to swallow): Neurological emergency. Immediate IM/SQ glucagon (0.5 mg if <25 kg; 1.0 mg if >25 kg) or IV dextrose.

Sick Day Management

• Intercurrent illness/infection induces severe insulin resistance.
• Cardinal Rule: Basal insulin must absolutely never be omitted.
• Withholding insulin precipitates DKA swiftly.
• Aggressive hourly SMBG/blood beta-hydroxybutyrate/urine ketone monitoring required.
• Treatment: Supplemental rapid-acting correction doses (10-20% Total Daily Dose) every 2-4 hours until ketosis clears.
• Continuous hydration mandatory (Sugar-free if BG > 250 mg/dL; Sugar-containing if BG < 250 mg/dL).

Chronic Complications & Screening

Associated Autoimmune Conditions

• High-risk HLA genotypes confer lifetime risk for overlapping autoimmune endocrinopathies.

Condition	Prevalence/Features	Screening Protocol
Hashimoto Disease	Most common (20-25% have antibodies).	Serum TSH, thyroperoxidase/thyroglobulin antibodies shortly after diagnosis, then every 1-2 years.
Celiac Disease	4-15% prevalence. Silent or unpredictable hypoglycemia/poor weight gain.	tTG-IgA + total IgA at diagnosis, 2 years, and 5 years.
Addison Disease	Rare, life-threatening. Unexplained decreased insulin need, severe fatigue, hyperpigmentation.	21-hydroxylase autoantibodies or basal cortisol.
APS Type 1/2	Autoimmune Polyglandular Syndromes.	Evaluate if T1DM coexists with Addison, Hashimoto, or mucocutaneous candidiasis.

Microvascular Complications

• Tied to cumulative disease duration and glucotoxicity.

Complication	Pathological Findings	Screening Protocol	Intervention
Nephropathy	Persistent microalbuminuria (20-200 $\mu$g/min or 30-300 mg/g ratio).	Annual spot urine albumin-to-creatinine. Start age 11/puberty after 2-5 yrs duration.	ACE inhibitors or ARBs.
Retinopathy	Capillary microaneurysms, proliferative vascular disease.	Annual dilated fundus exam. Start age 11/puberty after 3-5 yrs duration.	-
Neuropathy	Distal symmetric polyneuropathy, autonomic neuropathy.	Annual comprehensive foot exam (vibration, proprioception). Start age 11/puberty after 2-5 yrs.	-

Macrovascular Disease

• Accelerated risk of atherosclerotic cardiovascular disease, ischemic heart disease, stroke.

Condition	Screening Protocol	Target/Intervention
Dyslipidemia	Fasting lipid profile $\ge$ 10 years of age (once glycemic control established).	Target LDL < 100 mg/dL. Repeat annually if abnormal; every 3-5 years if normal.
Hypertension	Blood pressure measured/plotted on percentiles at every routine clinic visit.	Early intervention to prevent synergistic worsening of nephropathy/CV risk.

Specific Pediatric Complications

Syndrome/Condition	Etiology	Clinical Characteristics
Mauriac Syndrome	Chronic, profound under-insulinization and poor metabolic control.	Severe growth failure, delayed puberty, massive hepatomegaly (glycogen/fat deposition), cushingoid facies, proximal muscle wasting.
Cheiroarthropathy	Accumulation of advanced glycation end products/collagen cross-linking in periarticular tissues.	Limited Joint Mobility. Painless stiffness/flexion contractures of metacarpophalangeal/proximal interphalangeal joints. Strong predictor of microvascular disease.